CytomX Therapeutics Inc (NASDAQ:CTMX) insider Sean A. Mccarthy sold 6,526 shares of CytomX Therapeutics stock in a transaction on Friday, November 2nd. The shares were sold at an average price of $15.00, for a total value of $97,890.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of CTMX opened at $12.75 on Wednesday. CytomX Therapeutics Inc has a 52-week low of $12.75 and a 52-week high of $35.00.
CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.11). CytomX Therapeutics had a negative net margin of 44.46% and a negative return on equity of 74.84%. Analysts anticipate that CytomX Therapeutics Inc will post -1.58 EPS for the current year.
Several institutional investors and hedge funds have recently modified their holdings of CTMX. UBS Group AG increased its stake in shares of CytomX Therapeutics by 311.3% in the 1st quarter. UBS Group AG now owns 45,937 shares of the biotechnology company’s stock valued at $1,307,000 after purchasing an additional 34,767 shares during the last quarter. WINTON GROUP Ltd bought a new position in shares of CytomX Therapeutics in the 1st quarter valued at $205,000. Allianz Asset Management GmbH increased its stake in shares of CytomX Therapeutics by 7.4% in the 1st quarter. Allianz Asset Management GmbH now owns 58,739 shares of the biotechnology company’s stock valued at $1,671,000 after purchasing an additional 4,036 shares during the last quarter. Xact Kapitalforvaltning AB bought a new position in shares of CytomX Therapeutics in the 2nd quarter valued at $206,000. Finally, Essex Investment Management Co. LLC bought a new position in shares of CytomX Therapeutics in the 2nd quarter valued at $502,000. Institutional investors own 71.53% of the company’s stock.
Several equities analysts have weighed in on the company. Cann reaffirmed a “hold” rating on shares of CytomX Therapeutics in a report on Tuesday. BidaskClub raised CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 17th. ValuEngine cut CytomX Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 29th. Zacks Investment Research cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 9th. Finally, HC Wainwright set a $32.00 price objective on CytomX Therapeutics and gave the company a “buy” rating in a report on Wednesday, October 24th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $34.88.
ILLEGAL ACTIVITY NOTICE: “Sean A. Mccarthy Sells 6,526 Shares of CytomX Therapeutics Inc (CTMX) Stock” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/11/07/sean-a-mccarthy-sells-6526-shares-of-cytomx-therapeutics-inc-ctmx-stock.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Further Reading: Understanding Market Liquidity
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.